LONDON - Ananda, a company operating in the cannabinoid therapy sector, announced today that it has officially rebranded to ANANDA PHARMA plc. The company, traded on the AQUIS Stock Exchange under the ticker ANA, specializes in developing treatments for complex conditions using cannabinoids.
The name change is set to take effect on the AQUIS exchange at 8:00 a.m. on December 23, 2024. Despite the rebranding, the company's ticker 'ANA' and financial identifiers, including its ISIN (GB00BDQPXQ60) and SEDOL (BDQPXQ6), will remain the same. The rebranding also includes a new website address, www.anandapharma.co.uk, and an update to the company's logo and branding.
Melissa Sturgess, the CEO of Ananda, stated that the name change underscores the company's dedication to advancing licensed cannabinoid medicines to patients. She emphasized the company's strategy to focus on the biopharmaceutical drug development pathway as a means to support patients and provide shareholder value.
Existing shareholders are advised that the change of name will not affect their shareholdings. Current share certificates are still valid and should be retained. Any future share certificates issued will display the new name of the company, ANANDA PHARMA plc.
The company's decision to adopt a new name and branding is part of its strategic initiative to better align with its core business and long-term objectives in the biopharmaceutical industry. This announcement is based on a press release statement issued by the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.